Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial

Ramsay, Crichton; Pearson, Darcy; Mildenhall, S; Wilson, Andrew

doi:10.1136/thx.2010.135038

Cited by 51 publications

(34 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Ramsay et al, 14 randomized 73 patients and found a significantly higher peak expiratory flows (PEFs) measured in the morning after admission in patients who received montelukast (p=0.046, 95% CI of 1.15-113.6 L/min) as compared to placebo group. Gaddy et al, 15 showed that intravenous leukotriene receptor antagonists could produce a 22% improvement in FEV1 from baseline in those with stable asthma with a baseline FEV1 of 50% -80% predicted.…”

Section: Discussionmentioning

confidence: 88%

“…Our study showed there was significant improvement in PEFR at 2 weeks in the study group as compared to the control group (3.31±1.53l/sec vs 2.91±1.24l/sec; p<0.0376). Ramsay et al 14 , in a randomized double blind placebo controlled study, has observed that patients who received Montelukast had a significantly higher PEFR values than those who received placebo the morning after admission with a difference of 57.4l/min (p<0.04).…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Role of Oral Montelukast in Acute Asthma Exacerbations : A Randomized Placebo Controlled Trial

Gajanan¹,

Chaudhury²,

Hattiholi³

2015

jemds

View full text Add to dashboard Cite

BACKGROUND: Leukotriene receptor antagonists (LTRAs) are well established in the management of outpatient asthma. However, there is very little information as to their role in acute asthma exacerbations. The present study was done to evaluate the clinical efficacy of oral Montelukast as an add on therapy to the usual standard therapy of acute attack of bronchial asthma. MATERIALS AND METHODS:A randomized single blinded controlled study was conducted in a tertiary care teaching hospital. A total of 320 patients with age >18 years of acute exacerbations due to bronchial asthma were included in the study. The patients were randomized into two study and control groups. The study group patients received oral Montelukast (10mg) once daily for 2 weeks, while the control group received a placebo. All the patients received standard therapy according to GINA guidelines. Improvements in lung function tests, clinical symptoms and relapse rates were monitored at baseline, at discharge and at 2 weeks. Side effects profile was also monitored. RESULTS: A total of 255 patients were finally assessed. One hundred thirty patients belonged to study group and 125 in the control group. Baseline characteristics were similar and well matched in both the groups. Mean age was 39.9±15.8 years in study group and 42.8±12.8 in the control group and majority were female patients in both the groups. At the end of 2 weeks, it was observed that there were no significant improvements in FEV1 and FVC as compared to the control group. However, there was significant improvement in PEFR at 2 weeks (0.4 L/sec, 12%) as compared to the control group (p <0.0376). Length of hospital stay was similar in both the groups. No serious adverse effects were noted during the course of the study. CONCLUSIONS: In acute asthma exacerbations, the present study showed that additional administration of oral Montelukast resulted in significantly higher PEFR at 2 weeks as compared to the standard treatment alone. These findings should be confirmed by conducting a larger population based clinical study.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 97%

Role of Oral Montelukast in Acute Asthma Exacerbations : A Randomized Placebo Controlled Trial

Gajanan¹,

Chaudhury²,

Hattiholi³

2015

jemds

View full text Add to dashboard Cite

show abstract

“…Small studies have demonstrated improvement in lung function 389,390 but the clinical role of these agents requires more study.…”

Section: Leukotriene Receptor Antagonistsmentioning

confidence: 99%

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Kumbhare

Strange

2018

Southern Medical Journal

View full text Add to dashboard Cite

“…Leucotriene antagonists (in addition to corticosteroids) Recent trials have suggested that there may be a role for iv [107] and even oral [108] leucotriene antagonist therapy in acute severe asthma, but until this is added to updated guidelines, it is unlikely to gain widespread use.…”

Section: Adrenalinementioning

confidence: 99%

Medical emergencies: pulmonary embolism and acute severe asthma

Somasundaram

Ball

2012

Anaesthesia

View full text Add to dashboard Cite

show abstract

Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial

Cited by 51 publications

References 29 publications

Role of Oral Montelukast in Acute Asthma Exacerbations : A Randomized Placebo Controlled Trial

Role of Oral Montelukast in Acute Asthma Exacerbations : A Randomized Placebo Controlled Trial

Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States

Medical emergencies: pulmonary embolism and acute severe asthma

Contact Info

Product

Resources

About